CD137 Agonist Antibody - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “CD137 Agonist Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in CD137 Agonist Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
CD137 Agonist Antibody: Overview
CD137, also known as 4-1BB, has long been known as a target of interest for cancer. It is a costimulatory immunoreceptor and a member of the TNF-receptor family. The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Agonistic anti-CD137 antibody enhances anti-cancer immunity to protect from solid tumors. This outcome is due to an active effect of cytotoxic T cells, NK cells, and macrophages by this antibody.
'CD137 Agonist Antibody - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CD137 Agonist Antibody pipeline landscape is provided which includes the disease overview and CD137 Agonist Antibody treatment guidelines. The assessment part of the report embraces, in depth CD137 Agonist Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CD137 Agonist Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the CD137 Agonist Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD137 Agonist Antibody Emerging Drugs
Further product details are provided in the report……..
CD137 Agonist Antibody: Therapeutic Assessment
This segment of the report provides insights about the different CD137 Agonist Antibody drugs segregated based on following parameters that define the scope of the report, such as:
CD137 Agonist Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD137 Agonist Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD137 Agonist Antibody drugs.
CD137 Agonist Antibody Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “CD137 Agonist Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in CD137 Agonist Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CD137 Agonist Antibody: Overview
CD137, also known as 4-1BB, has long been known as a target of interest for cancer. It is a costimulatory immunoreceptor and a member of the TNF-receptor family. The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. CD137 (4-1BB) is a member of the TNFR superfamily that represents a promising target for cancer immunotherapy. Agonistic anti-CD137 antibody enhances anti-cancer immunity to protect from solid tumors. This outcome is due to an active effect of cytotoxic T cells, NK cells, and macrophages by this antibody.
'CD137 Agonist Antibody - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CD137 Agonist Antibody pipeline landscape is provided which includes the disease overview and CD137 Agonist Antibody treatment guidelines. The assessment part of the report embraces, in depth CD137 Agonist Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CD137 Agonist Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence CD137 Agonist Antibody R&D. The therapies under development are focused on novel approaches to treat/improve CD137 Agonist Antibody.
This segment of the CD137 Agonist Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD137 Agonist Antibody Emerging Drugs
- Utomilumab: Pfizer
- LVGN6051: Lyvgen
- AGEN2373: Agenus, Inc.
Further product details are provided in the report……..
CD137 Agonist Antibody: Therapeutic Assessment
This segment of the report provides insights about the different CD137 Agonist Antibody drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in CD137 Agonist Antibody
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
CD137 Agonist Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD137 Agonist Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD137 Agonist Antibody drugs.
CD137 Agonist Antibody Report Insights
- CD137 Agonist Antibody Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CD137 Agonist Antibody drugs?
- How many CD137 Agonist Antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD137 Agonist Antibody?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD137 Agonist Antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CD137 Agonist Antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
CD137 Agonist Antibody: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CD137 Agonist Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CD137 Agonist Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CD137 Agonist Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Utomilumab: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LVGN6051: Lyvgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CD137 Agonist Antibody Key Companies
CD137 Agonist Antibody Key Products
CD137 Agonist Antibody- Unmet Needs
CD137 Agonist Antibody- Market Drivers and Barriers
CD137 Agonist Antibody- Future Perspectives and Conclusion
CD137 Agonist Antibody Analyst Views
CD137 Agonist Antibody Key Companies
Appendix
Executive Summary
CD137 Agonist Antibody: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CD137 Agonist Antibody – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CD137 Agonist Antibody companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CD137 Agonist Antibody Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Utomilumab: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LVGN6051: Lyvgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CD137 Agonist Antibody Key Companies
CD137 Agonist Antibody Key Products
CD137 Agonist Antibody- Unmet Needs
CD137 Agonist Antibody- Market Drivers and Barriers
CD137 Agonist Antibody- Future Perspectives and Conclusion
CD137 Agonist Antibody Analyst Views
CD137 Agonist Antibody Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for CD137 Agonist Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for CD137 Agonist Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for CD137 Agonist Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for CD137 Agonist Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
